| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Pathology and Laboratory Medicine and 2 Urology, 3 Center for Clinical Epidemiology and Biostatistics, and 4 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
Requests for reprints: Hanna Rennert, Department of Pathology and Laboratory Medicine University of Pennsylvania Health System, 7 Gates West, 3400 Spruce Street, Philadelphia, PA 19104. Phone: 215-662-7571; Fax: 215-614-1986. E-mail: hanna.rennert{at}uphs.upenn.edu
Reported associations of ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer have been inconsistent and understudied in African Americans. We evaluated the role of 16 sequence variants in these genes with prostate cancer using 888 European American and 131 African American cases, and 473 European American and 163 African American, controls. We observed significant differences in ELAC2, RNASEL, and MSR1 allele frequencies by race. However, we did not observe significant associations between prostate cancer and any variants examined for both races combined. Associations were observed when stratified by race, family history, or disease severity. European American men homozygous for MSR1 IVS7delTTA had an elevated risk for localized stage [odds ratio, (OR), 3.5; 95% confidence interval (95% CI), 1.4-6.9], low-grade (OR, 3.2; 95% CI, 1.4-7.3) disease overall, and with low-grade (OR, 2.9; 95% CI, 1.2-7.2) or late-stage disease (OR, 5.2; 95% CI, 1.1-25.7) in family history–negative African Americans. MSR1 Arg293X was associated with family history–negative high-grade disease (OR, 4.0; 95% CI, 1.1-14.1) in European Americans. RNASEL Arg462Gln was associated with low-grade (OR, 1.5; 95% CI, 1.04-2.2) and early-stage (OR, 1.5; 95% CI, 1.02-2.1) disease in family history–negative European Americans. In family history–positive individuals, Arg462Gln was inversely associated with low-grade (OR, 0.43; 95% CI, 0.21-0.88) and low-stage (OR, 0.46; 95% CI, 0.22-0.95) disease. In African Americans, Arg462Gln was associated with positive family history high-stage disease (OR, 14.8; 95% CI, 1.6-135.7). Meta-analyses revealed significant associations of prostate cancer with MSR1 IVS7delTTA, –14,742 A>G, and Arg293X in European Americans; Asp174Tyr in African Americans; RNASEL Arg462Gln in European American's overall and in family history–negative disease; and Glu265X in family history–positive European Americans. Therefore, MSR1 and RNASEL may play a role in prostate cancer progression and severity.
This article has been cited by other articles:
|
|
 |
|
  Y.-C. Chen, E. Giovannucci, P. Kraft, and D. J.Hunter Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study Carcinogenesis, May 1, 2008; 29(5): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Chen, E. Giovannucci, P. Kraft, and D. J. Hunter Association between Genetic Polymorphisms of Macrophage Scavenger Receptor 1 Gene and Risk of Prostate Cancer in the Health Professionals Follow-up Study Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 1001 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Hsing, L. C. Sakoda, J. Chen, A. P. Chokkalingam, I. Sesterhenn, Y.-T. Gao, J. Xu, and S.L. Zheng MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China Carcinogenesis, December 1, 2007; 28(12): 2530 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, F. R. Schumacher, S. J. Plummer, E. Jorgenson, G. Casey, and J. S. Witte trans-Fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant Carcinogenesis, June 1, 2007; 28(6): 1232 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Molinaro, B. K. Jha, K. Malathi, S. Varambally, A. M. Chinnaiyan, and R. H. Silverman Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells Nucleic Acids Res., December 2, 2006; 34(22): 6684 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J O'Loughlin, E Dugas, K Maximova, and N Kishchuk Reporting of ethnicity in research on chronic disease: update Postgrad. Med. J., November 1, 2006; 82(973): 737 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li and B. C. Tai RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis. Clin. Cancer Res., October 1, 2006; 12(19): 5713 - 5719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Rebbeck, C. H. Halbert, and P. Sankar Genetics, Epidemiology, and Cancer Disparities: Is it Black and White? J. Clin. Oncol., May 10, 2006; 24(14): 2164 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orr-Urtreger, A. Bar-Shira, D. Bercovich, N. Matarasso, U. Rozovsky, S. Rosner, S. Soloviov, G. Rennert, L. Kadouri, A. Hubert, et al. RNASEL Mutation Screening and Association Study in Ashkenazi and Non-Ashkenazi Prostate Cancer Patients. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 474 - 479. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
